Market Cap£37m

Last Close 0.05p

Respiri is an ASX-listed company developing SaaS diagnostic solutions to support respiratory health management. Its technology detects wheeze, a typical symptom of asthma, chronic obstructive pulmonary disease and respiratory disease, to provide an objective measure of airway limitation.

More Respiri content >

Investment summary

Respiri has announced that, along with partner Access Telehealth, it has successfully concluded a system integration of the companies’ platforms with the Michigan Children’s Hospital, the company’s first US customer. This includes Respiri’s proprietary wheezo device, application and health portal (which manages respiratory health data) along with Access Telehealth’s remote patient monitoring (RPM) platform, Remotli. Patient intake is expected to start in the coming weeks and would mark the first patient use of wheezo in the US, feedback from which is likely to set the direction for future uptake. We highlight that the market for wheezo in the US is expected to be physician led and, unlike Respiri’s domestic Australian market, is reimbursed under the relevant RPM procedural terminology codes. The US market therefore presents a significant opportunity for Respiri.

Content on Respiri
Respiri – Wheezo to begin patient use in the US
Healthcare | research QuickView | 1 August 2022
Edison QuickView
Respiri – NIHR funding to seek better outcomes
Healthcare | research QuickView | 13 July 2022
Edison QuickView
View more
Register to receive research on Respiri as it is published
Share price graph
Price performance
Actual (16.9) 4.3 (21.0)
Relative* (21.9) 9.8 (15.2)
52-week high/low 0.1p/0.0p
*% relative to local index